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Objective BMS-284756 (T-3811ME) is a novel des-F(6)-quinolone effective against a
broad spectrum of aerobic and anaerobic pathogens. The aim of this study was to
investigate the ecological effect of BMS-284756 on the intestinal microﬂora.
Methods Forty healthy subjects participated in the trial. Eight subjects were assigned to
each of ﬁve dose panels (100, 200, 400, 800 and 1200mg BMS-284756) and received daily
oral dosing with either BMS-284756 (n¼ 6) or placebo (n¼ 2) for 14 days. Fecal samples
were collected before (days2 and1), during (days 7 and 14), and after (days 21, 28, and
45) completion of the administration period.
Results In subjects receiving 100 or 200mg BMS-284756, no signiﬁcant changes in the
intestinal aerobic and anaerobic microﬂora occurred. The number of enterococci, bacilli,
corynebacteria, biﬁdobacteria, lactobacilli, clostridia and bacteroides decreased in sub-
jects receiving 400 or 800mg BMS-284756, whereas the number of eubacteria increased.
Subjects who received 1200mg BMS-284756 had signiﬁcant changes in the microﬂora:
enterococci, bacilli, corynebacteria, enterobacteria, biﬁdobacteria, lactobacilli, clostridia
and bacteroides were suppressed, whereas eubacteria and yeasts were increased.
Regardless of dose, the microﬂora returned to normal levels at day 28 (2weeks after
the administration of BMS-284756 was discontinued). Fecal concentrations of BMS-
284756 increased with the higher doses, from 35.7mg/kg (100mg) to 262.8mg/kg
(1200mg). These ecological ﬁndings should be considered if 800- or 1200-mg doses of
BMS-284756 are to be used for longer periods than 14 days.
Conclusion The ecological impact of BMS-284756 is selective, with results similar to
those described for other quinolones.
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INTRODUCTION
A common and signiﬁcant cause of disturbances in
the normal intestinal microﬂora is the administra-
tion of antimicrobial agents [1]. When the number
of micro-organisms is reduced during therapy,
resistance to colonization is decreased, which
may lead to several unwanted effects. One is
overgrowth of already present micro-organisms
with natural resistance, such as yeasts, which
may cause systemic infections in immunocompro-
mised patients, and Clostridium difﬁcile, whichmay
lead to diarrhea and/or colitis [1–5]. A second
consequence is the establishment of new resistant
pathogenic bacteria, which may also colonize
other areas of the host. In addition, bacterial over-
growth encourages the transfer of resistance fac-
tors among bacteria [6,7].
Several factors inﬂuence the extent to which a
given antimicrobial agent will reduce the normal
microﬂora. Antimicrobial drugs that are secreted
in the bile or from the intestinal mucosa can reach
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the colon in active form, where they suppress sus-
ceptible micro-organisms and disturb the ecologi-
cal balance in the normal intestinal microﬂora [1].
BMS-284756 (T-3811ME) is a novel des-F(6)-qui-
nolone. Its chemical name is 1-cyclopropyl-8-(di-
ﬂuoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-
5-isoindolyl]-4-oxo-1,4-dihydro-3-quinolinecarbo-
xylic acid methanesulfonate monohydrate. It is a
broad-spectrum quinolone that does not contain
the ﬂuorine substituent at position C6 that is
typical of existing ﬂuoroquinolones [8]. Although
previous analyses of the structure–activity rela-
tionship had suggested that the 6-ﬂuoro group
imparts enhanced gyrase inhibition and bacterial
penetration, more recent chemical assessments
suggested that the interactions between the sub-
stituent at the 8-position and the N-1 cyclopropyl
groups can yield surprisingly potent and broad-
spectrum activities. BMS-284756 represents a
breakthrough in the quinolone drug class, result-
ing in a unique pattern of bacterial susceptibilities,
including staphylococci and streptococci (e.g.
penicillin-resistant Streptococcus pneumoniae and
some methicillin-resistant Staphylococcus aureus),
enterobacteria, anaerobic bacteria and mycoplas-
mas [8–11].
Development and assessment of new ﬂuoroqui-
nolones is an important priority because results
from a number of recent surveillance studies have
indicated the emergence of resistance to older
drugs in this class by clinically important Gram-
positive and Gram-negative pathogens [12–15]. In
addition, some of the newer and more potent
ﬂuoroquinolones are limited by potentially serious
side-effects, including hepatotoxicity, phototoxi-
city, and arrhythmogenicity (i.e. QTc prolonga-
tion) [16,17].
The aim of the present study was to investigate




Forty healthy subjects (eight women and 32 men;
mean age 33 years, range 18–45 years) participated
in the study. All subjects were considered healthy,
based on their medical history and clinical and
laboratory investigations. None of the subjects had
been given any antimicrobial agents during the
previousmonth. No othermedicationwas allowed
during the investigation period.
Drug administration
Eight subjects were assigned to each of ﬁve dose
panels (100, 200, 400, 800 and 1200mg). Within
each dose panel, the subjects were randomized in a
3 : 1 ratio to receive BMS-284756 or placebo. The
subjects received daily oral dosing with either
BMS-284756 (n¼ 6) or placebo (n¼ 2) for 14 days.
When a dose regimen was found to be safe and
tolerated, the succeeding panel of eight subjects
received the next higher dose of BMS-284756
(n¼ 6) or placebo (n¼ 2).
Sampling of fecal specimens
To evaluate the effect of BMS-284756 on the intest-
inal ﬂora, fecal samples (10 g each) were collected
on days 2, 1, 7, 14, 21, 28 and 45. Subjects were
admitted to the clinical unit a day before the fecal
sampling on days 21, 28 and 45 and were given
prune juice, if warranted, to ensure the collection
of a fecal specimen.
For the fecal samples collected while subjects
were in the study facility, 10-g aliquots of each
sample were transferred immediately to an appro-
priately labeled sterile screw-cap tube, frozen
immediately, and stored at 70 8C.
For fecal samples collected while subjects
were not in the study facility, 10-g aliquots of
each sample were transferred immediately to
an appropriately labeled sterile screw-cap tube,
frozen immediately, and stored in the subject’s
household freezer. The aliquots were submitted
to the study personnel within 24 h of collec-
tion and stored at 70 8C. The samples were
shipped on dry ice to the microbiological labo-
ratory.
Determination of BMS-284756 fecal
concentrations
The concentrations of BMS-284756 in the fecal
samples were determined by the agar-well diffu-
sion method. The test medium was Antibiotic
Medium no. 1 (Difco, Detroit, MI, USA), and the
indicator strain wasMicrococcus luteusATCC 9341.
Samples were run in duplicate, and a concomitant
standard series was inoculated on each agar plate.
The plates were incubated for 18 h at 37 8C. Con-
centrations of BMS-284756 were determined rela-
tive to the diameters of the inhibition zones caused
by the known concentrations from the standard
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series. The detection limit was 0.5mg/kg, and the
coefﬁcient of variation was below 5%.
Processing of fecal specimens for
microbiological analysis
The stool specimens were suspended in pre-
reduced peptone–yeast extract medium, diluted
to 107, and inoculated on non-selective and
selective media. The following agar media were
used: blood agar (Kemila, Lab M, Bury, UK) for
total aerobes and anaerobes, CLED agar (Merck,
Darmstadt, Germany) for detection of Enterobac-
teriaceae, Enterococcosel agar (BBL, Cockeysville,
MD, USA) for detection of enterococci, Sabouraud
agar (Difco) for detection of yeasts, Rogosa agar
(Difco) for cultivation of lactobacilli, BL agar
(Difco) for cultivation of biﬁdobacteria, kanamy-
cin–vancomycin–blood agar for cultivation of
Bacteroides and Prevotella species, neomycin–
vancomycin–blood agar for cultivation of fuso-
bacteria, veillonella agar (Difco) for cultivation of
Veillonella cocci, egg-yolk agar (Oxoid, Basingstoke,
UK) for cultivation of clostridia, and taurocholate–
cycloserine–cefoxitin–fructose agar (peptone from
casein/proteose peptone no. 3 40mg/mL, sodium
hydrogen phosphate 5mg/mL, potassium dihy-
drogen phosphate 1mg/mL, sodium chloride
2mg/mL, sodium sulfate 0.2mg/mL, Bacto
agar/agar–agar 20mg/mL, taurocholic acid
1mg/mL, neutral red 0.03mg/mL, 15% fructose,
C. difﬁcile supplement D-cycloserine, cefoxitin) for
detection of C. difﬁcile. The aerobic agar plates
were incubated for 48 h at 37 8C and the anaerobic
plates were incubated for 48 h at 37 8C in GasPak
anaerobic jars (BBL). After incubation, different
colony types were counted, isolated in pure cul-
ture, and identiﬁed to genus level. All isolates
were analysed according to Gram reaction and
cell and colony morphology, followed by different
biochemical tests. AnAPI-20E test kit (BioMe´rieux,
Marcy l’Etoile, France) was used for the identi-
ﬁcation of Enterobacteriaceae. The anaerobic
micro-organisms were identiﬁed by gas–liquid
chromatography of metabolites from glucose.
The lower limit of detection was 102 micro-
organisms/g feces.
BMS-284756 susceptibility tests
Three quantitative representative colonies of
enterococci, enterobacteria and bacteroides were
isolated from each subject on days 0, 14 and 45 to
study the susceptibility of BMS-284756 during the
investigation period. The minimum inhibitory
concentrations (MICs) for BMS-284756 were deter-
mined by the agar dilution method using PDM
Antibiotics Sensitivity Medium (AB Biodisk,
Solna, Sweden). Escherichia coliATCC 25922, Enter-
ococcus faecalis ATCC 29212, and Bacteroides fragilis
NCTC 9343 were used as reference strains. The
inoculum was 107 colony-forming units per milli-
liter (CFU/mL) for aerobic strains and 108CFU/
mL for Bacteroides spp. strains. The agar plates
were incubated aerobically or anaerobically at
37 8C for 24 or 48 h, respectively.
Statistical methods
Descriptive statistics were calculated for the
values estimated for the fecal specimens, i.e. intest-
inal microﬂora as log numbers of micro-organ-
isms/g feces and fecal concentrations of BMS-
284756. Fecal values were plotted by the different
dose levels of BMS-284756.
RESULTS
Impact of BMS-284756 on the intestinal
microflora in subjects receiving 100 or 200mg
once daily for 14 days
The numbers of enterococci, staphylococci, bacilli,
corynebacteria, enterobacteria and candida did
not change signiﬁcantly during the observation
period for the patients treated with either 100 or
200mg/day BMS-284756. There appeared to be a
slight, but insigniﬁcant, depression in the number
of bacilli and corynebacteria during treatment
and recovery by day 21 in the subjects who rece-
ived either the 100 or 200mg/day BMS-284756
doses. There was also a slight post-treatment
rise in the number of enterococci among the sub-
jects who received 200mg/day BMS-284756. For
anaerobic microﬂora, there were minor decreases
in the number of clostridia during treatment,
which then recovered by day 21 for both the 100
and 200mg/day doses. There was also a slight
decline in the number of bacteroides during treat-
ment for the subjects who received 200mg/day
BMS-284756 and an insigniﬁcant increase in the
number of eubacteria. Numbers of both of these
organisms returned to pretreatment levels by
day 14.
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Impact of BMS-284756 on the intestinal
microflora in subjects receiving 400mg once
daily for 14 days
Figure 1 presents the ﬁndings for the aerobic
intestinal microﬂora. The number of enterococci,
bacilli and corynebacteria decreased during the
administration period but returned to normal
levels after 14 days (P 0.05). The numbers of
biﬁdobacteria, lactobacilli, clostridia and bacter-
oides were suppressed and the numbers of eubac-
teria increased during the administration of BMS-
284756 (P 0.05) (Figure 2). The anaerobic micro-
ﬂora also returned to normal after 14 days.
Figure 1 Impact of BMS-284756 given as 400-mg capsules
daily for 14 days on the intestinal aerobic microflora in six
subjects. Line indicates median value of the logarithmic
number of micro-organisms/g feces.
Figure 2 Impact of BMS-284756 given as 400-mg capsules
daily for 14 days on the intestinal anaerobic microflora in
six subjects. Line indicates median value of the logarithmic
number of micro-organisms/g feces.
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Impact of BMS-284756 on the intestinal
microflora in subjects receiving 800mg once
daily for 14 days
Enterococci, bacilli and corynebacteria decreased
markedly (P 0.05), but there were no other chan-
ges in the aerobic intestinal microﬂora (Figure 3).
Figure 4 shows the impact on the anaerobic intest-
inal microﬂora. Biﬁdobacteria, lactobacilli, clostri-
dia and bacteroides were suppressed and
eubacteria increased during the administration
(P 0.05) and returned to normal levels after
14 days.
Figure 3 Impact of BMS-284756 given as 800-mg capsules
daily for 14 days on the intestinal aerobic microflora in six
subjects. Line indicates median value of the logarithmic
number of micro-organisms/g feces.
Figure 4 Impact of BMS-284756 given as 800-mg capsules
daily for 14 days on the intestinal anaerobic microflora in
six subjects. Line indicates median value of the logarithmic
number of micro-organisms/g feces.
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Impact of BMS-284756 on the intestinal
microflora in subjects receiving 1200mg once
daily for 14 days
The numbers of enterococci, bacilli, corynebacteria
and enterobacteria decreased signiﬁcantly during
the administration of 1200mg BMS-284756 (P
0.01), but normalized after 2weeks (Figure 5).
The levels of these bacteria declined to 2 log per
gram feces on days 7 and 14 and returned
to pretreatment levels by day 21 (enterococci) or
28 (bacilli, corynebacteria, and enterobacteria).
There were no signiﬁcant changes in either
staphylococci or candida. Figure 6 presents the
impact on the anaerobic intestinal microﬂora.
Figure 5 Impact of BMS-284756 given as 1200-mg capsules
daily for 14 days on the intestinal aerobic microflora in six
subjects. Line indicates median value of the logarithmic
number of micro-organisms/g feces.
Figure 6 Impact of BMS-284756 given as 1200-mg capsules
daily for 14 days on the intestinal anaerobic microflora in
six subjects. Line indicates median value of the logarithmic
number of micro-organisms/g feces.
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Among the anaerobic bacteria, eubacteria
increased from 2 log to about 6 log per gram
feces during dosing and returned to pretreatment
levels by day 21. Biﬁdobacteria, lactobacilli, clos-
tridia and bacteroides all decreased signiﬁcantly
(P 0.01) to 2 log per gram feces during dosing.
Clostridia returned to pretreatment levels by day
21, and biﬁdobacteria, lactobacilli and bacteroides
all normalized by 2weeks after the end of
BMS-284756 administration. Treatment with
Figure 7 Impact of placebo capsules given daily for
14 days on the intestinal aerobic microflora in 10 subjects.
Line indicates median value of the logarithmic number of
micro-organisms/g feces.
Figure 8 Impact of placebo capsules given daily for
14 days on the intestinal anaerobic microflora in 10
subjects. Line indicates median value of the logarithmic
number of micro-organisms/g feces.
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BMS-284756 had no effect on the numbers of
anaerobic cocci.
Impact of placebo administration on the
intestinal microflora in subjects receiving
placebo capsules once daily for 14 days
Figure 7 presents the impact of placebo adminis-
tration on the intestinal aerobic microﬂora. No
signiﬁcant changes were observed during the
investigation period. The same results were found
among the anaerobic bacteria (Figure 8).
Concentrations of BMS-284756 in feces
The fecal concentrations of BMS-284756 in subjects
receiving 100, 200, 400, 800 and 1200mg are given
in Table 1. The fecal concentrations of BMS-284756
correlated to the doses given.
In vitro susceptibility of isolated enterococci,
enterobacteria and bacteroides to different doses
of BMS-284756
Table 2 shows the in vitro susceptibility of isolated
enterococci, enterobacteria and bacteroides to
BMS-284756. In the subjects receiving placebo,
all enterococci had MIC values of 0.25mg/L or
less on days 0, 14 and 45. Increased MIC values for
enterococci were observed with increasing doses
of BMS-284756 (100mg, range 0.125–8.0mg/L;
Table 1 Fecal concentrations (mg/kg) of BMS-284756 in
the subjects receiving 100-mg, 200-mg, 400-mg, 800-mg, or
1200-mg capsules once daily for 14 days
Day Mean SD Median Range
100mg BMS-284756 (n¼ 6)
0 0 0 0 0
7 25.2 9 27.8 11.1–35.7
14 21.8 7.8 23.3 11.1–32.1
21 1.1 2.7 0 0–6.6
28 0 0 0 0
45 0 0 0 0
200mg BMS-284756 (n¼ 5)
0 0 0 0 0
7 35.3 9.7 35.9 22.8–48.3
14 38.2 8.4 38.7 29.4–49.2
21 3.7 8.2 0 0–18.3
400mg BMS-284756 (n¼ 6)
0 0 0 0 0
7 57.1 14.0 53.7 40.0–76.7
14 68.6 23.6 71.1 40.0–102.2
21 0 0 0 0
800mg BMS-284756 (n¼ 6)
0 0 0 0 0
7 106.5 39.6 109.8 45.6–159.0
14 124.2 23.9 132.8 89.7–148.8
21 10.5 24.3 0.5 0–60.0
1200mg BMS-284756 (n¼ 6)
0 0 0 0 0
7 190.7 52.8 165.3 144.0–262.8
14 177.0 38.2 160.2 140.9–236.9
21 16.4 18.1 11.4 0–44.7
No fecal concentrations of BMS-284756 were found in
samples from days 28 and 45.
Table 2 In vitro sensitivity of enterococci, enterobacteria and bacteroides isolated from the intestinal microflora to different





strains MIC50 MIC90 Range
100mg BMS-284756
Enterococci Day 0 4 15 0.25 8 0.016–8
Enterococci Day 14 0 0 – – –
Enterococci Day 45 5 12 0.25 8 0.125–8
Enterobacteria Day 0 3 9 0.032 1 0.032–1
Enterobacteria Day 14 1 2 0.125 0.125 0.125
Enterobacteria Day 45 4 12 0.125 0.25 0.125–0.25
Bacteroides Day 0 6 17 1 16 0.5–32
Bacteroides Day 14 4 12 8 16 2–32
Bacteroides Day 45 6 18 8 32 2–32
200mg BMS-284756
Enterococci Day 0 3 9 0.25 8 0.25–8
Enterococci Day 14 2 6 0.25 4 0.25–4
Enterococci Day 45 4 10 0.5 8 0.125–8
Enterobacteria Day 0 5 13 0.032 0.064 0.016–0.125
Enterobacteria Day 14 0 0 – – –
Enterobacteria Day 45 4 10 0.064 0.064 0.032–0.125
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200mg, range 0.125–8.0mg/L; 400mg, range
0.125–4.0mg/L; 800mg, range 0.25–4.0mg/L;
1200mg, range 0.032–8.0mg/L). The enterobac-
teria were more susceptible than the enterococci
in the placebo group, and in the groups receiving
100, 200, 400 and 800mg BMS-284756, the MIC
values ranged from 0.032 to 2.0mg/L. In the group
receiving 1200mg BMS-284756, increased MIC
values for enterobacteria were observed after
14 days of treatment with BMS-284756. Strains of
Bacteroides spp. were signiﬁcantly less susceptible
to BMS-284756 during and after treatment than
were enterococci and enterobacteria. On day 14,






strains MIC50 MIC90 Range
Bacteroides Day 0 5 15 1 2 0.25–4
Bacteroides Day 14 4 12 16 32 8–128
Bacteroides Day 45 4 12 16 64 0.25–64
400mg BMS-284756
Enterococci Day 0 3 7 0.25 4 0.064–4
Enterococci Day 14 2 4 4 4 0.5–4
Enterococci Day 45 4 12 0.25 0.5 0.125–0.5
Enterobacteria Day 0 3 9 0.032 0.064 0.032–0.064
Enterobacteria Day 14 0 0 – – –
Enterobacteria Day 45 1 3 0.125 0.125 0.125
Bacteroides Day 0 6 18 2 32 0.5–32
Bacteroides Day 14 2 6 16 32 16–32
Bacteroides Day 45 5 16 1 64 0.5–128
800mg BMS-284756
Enterococci Day 0 5 13 0.25 2 0.25–4
Enterococci Day 14 0 0 – – –
Enterococci Day 45 6 18 0.25 2 0.032–2
Enterobacteria Day 0 5 14 0.064 0.125 0.032–2
Enterobacteria Day 14 0 0 – – –
Enterobacteria Day 45 2 3 0.064 0.064 0.064
Bacteroides Day 0 6 18 1 4 0.25–32
Bacteroides Day 14 2 6 32 32 32
Bacteroides Day 45 4 12 8 32 1–128
1200mg BMS-284756
Enterococci Day 0 5 13 0.25 0.5 0.032–0.5
Enterococci Day 14 6 0 – – –
Enterococci Day 45 6 16 0.25 8 0.032–8
Enterobacteria Day 0 6 16 0.064 0.25 0.032–16
Enterobacteria Day 14 1 3 64 64 64–128
Enterobacteria Day 45 4 11 0.125 64 0.125–64
Bacteroides Day 0 5 15 1 1 0.5–4
Bacteroides Day 14 1 3 64 64 64
Bacteroides Day 45 5 13 8 8 0.5–32
Placebo capsules
Enterococci Day 0 4 11 0.125 0.125 0.064–0.25
Enterococci Day 14 2 6 0.25 0.25 0.25
Enterococci Day 45 6 16 0.25 0.25 0.032–0.25
Enterobacteria Day 0 4 10 0.064 0.125 0.032–0.25
Enterobacteria Day 14 6 15 0.064 0.125 0.032–0.25
Enterobacteria Day 45 5 12 0.064 0.25 0.032–0.5
Bacteroides Day 0 9 26 0.5 1 0.25–2
Bacteroides Day 14 8 23 0.5 1 0.25–32
Bacteroides Day 45 7 21 1 1 0.5–4
MIC50 and MIC90, minimum concentration of antibiotic needed to inhibit the growth of 50% and 90%, respectively, of
bacteria.
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Bacteroides spp. strains ranged between 2 and
128mg/L. There was also a trend toward higher
MIC values for Bacteroides spp. strains with the
higher doses of BMS-284756.
DISCUSSION
Quinolones have a selective effect on the human
microﬂora, mainly directed against aerobic Gram-
negative bacteria such as enterobacteria [18].
Enterococci are partly suppressed by some quino-
lones, whereas the dominant anaerobic microﬂora
are less affected even by the new quinolones with
pronounced anaerobic activities, such as moxiﬂox-
acin and trovaﬂoxacin [18,19]. Overgrowth of C.
difﬁcile and yeasts seldom occurs, but development
of quinolone-resistant bacterial strains during
administration has been reported.
In the present investigation, the impact of BMS-
284756 was correlated to the doses given. When
higher doses were administered, marked effects
on the intestinal microﬂora were observed. The
numbers of enterococci, bacilli, corynebacteria,
enterobacteria, biﬁdobacteria, lactobacilli, clostri-
dia and bacteroides decreased, whereas the
number of eubacteria increased. The fecal concen-
trations of BMS-284756 were correlated to the
observed changes in the intestinal microﬂora,
with higher fecal concentrations associated with
more microbiological changes. Similar ﬁndings
have been described for other quinolones [18].
The high fecal concentrations also selected for
enterococci and enterobacteria resistant to BMS-
284756. The Bacteroides spp. strains were less sus-
ceptible to the quinolone agent compared with
enterococci and enterobacteria. The reason for this
selection is unclear and should be further investi-
gated. These ecological ﬁndings should be consid-
ered when higher doses (e.g. 800 or 1200mg) of
BMS-284756 are used for periods longer than
14days. However, minimal changes in aerobic
and anaerobic intestinal microﬂora should be
expected at the usual dose of 400mg once daily.
These results are similar to those described for
other new quinolones [18], and the ecological
impact, including acquired resistance to BMS-
284756, is selective.
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